Related Experiment Videos
Continuous subcutaneous terbutaline administration prolongs pregnancy after recurrent preterm labor
John C Morrison1, Suneet P Chauhan, C Shannon Carroll
1Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, USA.
American Journal of Obstetrics and Gynecology
|June 26, 2003
Summary
Continuous subcutaneous terbutaline (SQT) effectively prolongs pregnancy for women experiencing recurrent preterm labor (RPTL). This home-based treatment reduces neonatal complications and hospitalizations, offering significant cost savings.
Area of Science:
- Obstetrics and Gynecology
- Neonatal Medicine
- Pharmacology
Background:
- Recurrent preterm labor (RPTL) poses significant risks to both mother and infant.
- Effective tocolytic therapy is crucial for managing RPTL and improving neonatal outcomes.
Purpose of the Study:
- To evaluate the effectiveness of continuous subcutaneous terbutaline (SQT) administered at home for managing RPTL.
- To compare outcomes of SQT treatment with a control group receiving no tocolytic therapy.
Main Methods:
- A comparative study involving women with RPTL at less than 32 weeks' gestation.
- Continuous subcutaneous terbutaline (SQT) administered at home versus matched control patients receiving no tocolytic therapy.
Main Results:
- SQT significantly increased gestational age at delivery (over 37 weeks) and prolonged pregnancies (average 49.8 days vs. 24.5 days).
- SQT reduced the percentage of deliveries before 32 weeks (0% vs. 47%) and decreased maternal and neonatal hospitalizations.
- Significant cost reductions were observed, with $4.67 saved in newborn care costs for every dollar spent on SQT.
Conclusions:
- Continuous subcutaneous terbutaline (SQT) is an effective home-based treatment for RPTL.
- SQT significantly prolongs pregnancy, reduces serious neonatal complications, and lowers hospitalization durations and costs for mother and infant.